Entropy Measures Quantify Global Splicing Disorders in Cancer

Most mammalian genes are able to express several splice variants in a phenomenon known as alternative splicing. Serious alterations of alternative splicing occur in cancer tissues, leading to expression of multiple aberrant splice forms. Most studies of alternative splicing defects have focused on the identification of cancer-specific splice variants as potential therapeutic targets. Here, we examine instead the bulk of non-specific transcript isoforms and analyze their level of disorder using a measure of uncertainty called Shannon's entropy. We compare isoform expression entropy in normal and cancer tissues from the same anatomical site for different classes of transcript variations: alternative splicing, polyadenylation, and transcription initiation. Whereas alternative initiation and polyadenylation show no significant gain or loss of entropy between normal and cancer tissues, alternative splicing shows highly significant entropy gains for 13 of the 27 cancers studied. This entropy gain is characterized by a flattening in the expression profile of normal isoforms and is correlated to the level of estimated cellular proliferation in the cancer tissue. Interestingly, the genes that present the highest entropy gain are enriched in splicing factors. We provide here the first quantitative estimate of splicing disruption in cancer. The expression of normal splice variants is widely and significantly disrupted in at least half of the cancers studied. We postulate that such splicing disorders may develop in part from splicing alteration in key splice factors, which in turn significantly impact multiple target genes.

[1]  Terry Gaasterland,et al.  Impact of alternative initiation, splicing, and termination on the diversity of the mRNA transcripts encoded by the mouse transcriptome. , 2003, Genome research.

[2]  Christopher J. Lee,et al.  Evidence that public database records for many cancer-associated genes reflect a splice form found in tumors and lack normal splice forms , 2005, Nucleic acids research.

[3]  Joshua M. Stuart,et al.  A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.

[4]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[5]  Dirk G Kieback,et al.  Expression of splicing factors in human ovarian cancer. , 2004, Oncology reports.

[6]  Christopher J. Lee,et al.  Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. , 2002, Nucleic acids research.

[7]  E. Lengyel,et al.  Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation , 2004, Oncogene.

[8]  Haibo Zhang,et al.  Biased alternative polyadenylation in human tissues , 2005, Genome Biology.

[9]  H. Jumaa,et al.  The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation , 1997, The EMBO journal.

[10]  Laurence J Miller,et al.  Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. , 2006, Cancer research.

[11]  F. Kittrell,et al.  Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis , 1999, Oncogene.

[12]  L. Dwyer-Nield,et al.  Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.

[13]  Bin Tian,et al.  Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing. , 2007, Genome research.

[14]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[15]  C. Bailly,et al.  Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. , 2001, Cancer research.

[16]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[17]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[18]  Hagen Blankenburg,et al.  The implications of alternative splicing in the ENCODE protein complement , 2007, Proceedings of the National Academy of Sciences.

[19]  Daniel Gautheret,et al.  AltTrans: Transcript pattern variants annotated for both alternative splicing and alternative polyadenylation , 2006, BMC Bioinformatics.

[20]  S. Burchill,et al.  FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells , 2003, British Journal of Cancer.

[21]  J. Castle,et al.  Genome-Wide Survey of Human Alternative Pre-mRNA Splicing with Exon Junction Microarrays , 2003, Science.

[22]  S. Brenner,et al.  Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements , 2007, Nature.

[23]  B. Frey,et al.  Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. , 2004, Molecular cell.

[24]  Stefan Stamm,et al.  Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. , 2004, Human molecular genetics.

[25]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[26]  A Jikko,et al.  Differential expression of the splicing regulatory factor genes during two-step chemical transformation in a BALB/3T3-derived cell line, MT-5. , 1999, Carcinogenesis.

[27]  S. Stamm,et al.  Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. , 2006, Cancer research.

[28]  Christopher J. Lee,et al.  Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. , 2003, Nucleic acids research.

[29]  S. Salzberg,et al.  The Transcriptional Landscape of the Mammalian Genome , 2005, Science.

[30]  C. V. Jongeneel,et al.  eVOC: a controlled vocabulary for unifying gene expression data. , 2003, Genome research.

[31]  Tyson A. Clark,et al.  Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. , 2007, Genes & development.

[32]  Phillip A. Sharp,et al.  Regulation of CD44 Alternative Splicing by SRm160 and Its Potential Role in Tumor Cell Invasion , 2006, Molecular and Cellular Biology.

[33]  R. Shamir,et al.  How prevalent is functional alternative splicing in the human genome? , 2004, Trends in genetics : TIG.

[34]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[35]  M. Garcia-Blanco,et al.  Alternative splicing in disease and therapy , 2004, Nature Biotechnology.

[36]  Denis Puthier,et al.  A General Survey of Thymocyte Differentiation by Transcriptional Analysis of Knockout Mouse Models1 , 2004, The Journal of Immunology.

[37]  G M Lenoir,et al.  A BRCA1 nonsense mutation causes exon skipping. , 1998, American journal of human genetics.

[38]  David Martin,et al.  GOToolBox: functional analysis of gene datasets based on Gene Ontology , 2004, Genome Biology.